Not all sufferers with CLL involve therapy. Even with all recent improvements, the iwCLL still recommends watchful observation for sufferers with asymptomatic sickness.86 This recommendation relies on not less than two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,1